Dysregulation of Insulin Secretion in Children With Congenital Hyperinsulinism due to Sulfonylurea Receptor Mutations

A. Grimberg, R.J. Ferry, Jr., A. Kelly, S. Koo-McCoy, K. Polonsky, B. Glaser, M.A. Permutt, L. Aguilar-Bryan, D. Stafford, P.S. Thornton, L. Baker, and Charles A. Stanley

Mutations in the high-affinity sulfonylurea receptor (SUR)-1 cause one of the severe recessively inherited diffuse forms of congenital hyperinsulinism or, when associated with loss of heterozygosity, focal adenomatosis. We hypothesized that SUR1 mutations would render the β-cell insensitive to sulfonylureas and to glucose. Stimulated insulin responses were compared among eight patients with diffuse hyperinsulinism (two mutations), six carrier parents, and ten normal adults. In the patients with diffuse hyperinsulinism, the acute insulin response to intravenous tolbutamide was absent and did not overlap with the responses seen in either adult group. There was positive, albeit significantly blunted, acute insulin response to intravenous dextrose in the patients with diffuse hyperinsulinism. Graded infusions of glucose, to raise and then lower plasma glucose concentrations over 4 h, caused similar rises in blood glucose but lower peak insulin levels in the hyperinsulinemic patients. Loss of acute insulin response to tolbutamide can identify children with diffuse SUR1 defects. The greater response to glucose than to tolbutamide indicates that ATP-sensitive potassium (K_{ATP}) channel–independent pathways are involved in glucose-mediated insulin release in patients with diffuse SUR1 defects. The diminished glucose responsiveness suggests that SUR1 mutations and lack of K_{ATP} channel activity may contribute to the late development of diabetes in patients with hyperinsulinism independently of subtotal pancreatectomy. *Diabetes* 50:322–328, 2001

From the Division of Pediatric Endocrinology (A.G., R.J.F., A.K., S.K.-M., L.B., C.A.S.), the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; the Division Endocrinology (K.P.), University of Chicago, Chicago, Illinois; the Division of Endocrinology and Metabolism (B.G.), Hebrew University, Jerusalem, Israel; the Division of Endocrinology and Metabolism (M.A.P.), Washington University, St. Louis, Missouri; the Division of Medicine (L.A.-B.), Baylor College of Medicine, Houston, Texas; the Division of Endocrinology (D.S.), Children's Hospital, Boston, Massachusetts; and the Division of Metabolism (P.S.T.), the Children's Hospital, Dublin, Ireland.

Address correspondence and reprint requests to Charles A. Stanley, MD, Division of Pediatric Endocrinology, the Children's Hospital of Philadelphia, 34th St. and Civic Center Blvd., Philadelphia, PA 19104. E-mail: stanley@email.chop.edu.

Received for publication 11 April 2000 and accepted in revised form 24 August 2000.

AIR, acute insulin response; K_{ATP} channel, ATP-sensitive potassium channel; Kir6.2, inwardly rectifying potassium channel; MODY, maturity-onset diabetes of the young; SUR, sulfonylurea receptor.

Several distinct forms of congenital hyperinsulinism have been identified in recent years (1). Sporadic nongenetic cases of transient hyperinsulinism can be associated with maternal diabetes and with perinatal stresses such as birth asphyxia or small-for-dates birth weight (2). Dominant genetic forms include activating glucokinase mutations that lower the glucose threshold for insulin release (3), gain-of-function mutations in glutamate dehydrogenase that cause both hyperinsulinism and hyperammonemia (4), and other types whose genetic bases have not yet been identified (5,6). However, mutations in the ATP-sensitive potassium (K_{ATP}) channel complex of the pancreatic β-cell plasma membrane cause some of the most severe clinical disease (7–11). Encoded by two adjacent genes on chromosome 11p, the sulfonylurea receptor (SUR)-1 regulates the channel activity, whereas the inwardly rectifying potassium channel (Kir6.2) constitutes the ion pore (12,13). Patients with K_{ATP} channel mutations who present the severe form of the disease are clinically diazoxide unresponsive, and many require 95% subtotal pancreatectomy to prevent recurrent hypoglycemia. They also exhibit a high risk of later developing diabetes, which is often attributed to their surgical treatment (14–16). SUR1 and Kir6.2 mutations can be expressed in two ways: autosomal recessive inheritance of two abnormal SUR1 or Kir6.2 alleles results in diffuse hyperinsulinism (formerly called nesidioblastosis), whereas inheritance of an abnormal paternal SUR1 allele with somatic loss of the maternal chromosome 11p15 leads to focal adenomatosis (17–19).

The K_{ATP} channel complex transduces the metabolic status of the β-cell into cell membrane electrical activity and thereby links insulin release with metabolic demands. SUR1, a member of the ATP-binding cassette superfamily, forms a hetero-octamer with Kir6.2 (20,21). Glucose entry and metabolism increase the ratio of ATP to ADP within the β-cell. At very high concentrations, ATP binding to Kir6.2 inhibits the channel activity, whereas magnesium nucleotides can antagonize this inhibition through interactions with the nucleotide binding folds of the SUR1 (22). The increased ATP-to-ADP ratio leads to closure of the K_{ATP} channel and hence depolarization of the β-cell membrane. The depolarization opens voltage-gated calcium channels, and the resultant elevation of the intracellular calcium concentration triggers exocytosis of insulin granules (23,24). Sulfonylureas modulate insulin secretion by binding to

TABLE 1
Clinical characteristics of the children with congenital hyperinsulinism

SUR1 genotype	Patient number	Sex	Age (years)	Age at presentation	Age at pancreatectomy	Current treatment
Diffuse hyperinsulinism						
DelF 1388/3992 –9 g → a	1	F	20	4 h	2 months	Frequent feedings
DelF 1388/3992 –9 g → a	2	F	14	Newborn	8 days	None
DelF 1388/3992 –9 g → a	3	F	13	11 months	ND*	None since age 8 years
DelF 1388/3992 –9 g → a	4	M	2	3 days	1, 2, 30 months*	Glucagon-octreotide infusion
3992 –9 g → a/3992 –9 g → a	5	M	13	10 days	ND	Frequent feedings
3992 –9 g → a/3992 –9 g → a	6	M	11	2 days	ND	Frequent gastrostomy feedings
3992 –9 g → a/3992 –9 g → a	7	F	6	1–2 days	1 month	None
3992 –9 g → a/3992 –9 g → a	8	M	4	At birth	1 month	None

*Surgery done after the time of the study; ND, no surgery.

SUR1; some, like tolbutamide, stimulate insulin secretion, whereas others, like diazoxide, inhibit it.

The present study was undertaken to test the hypothesis that mutations in SUR1, the metabolic transducer, would render the β-cell unresponsive to sulfonylureas and insensitive to high or rising glucose levels as well as to falling glucose levels. Insulin responses to tolbutamide, a sulfonylurea that stimulates insulin release, and to both acute and prolonged graded glucose stimulation were measured in children with diffuse SUR1$^{-/-}$ hyperinsulinism. The effects of heterozygous SUR1 mutations were investigated by evaluating insulin secretion in the heterozygous parents of these children.

RESEARCH DESIGN AND METHODS

Subject characteristics. The clinical characteristics of the eight children with diffuse SUR1$^{-/-}$ hyperinsulinism who were studied are shown in Table 1. They were aged 2–20 years. Patients 1 and 2 were sisters, and patients 5, 6, and 8 were brothers. All eight children were unresponsive to treatment with diazoxide, a drug that inhibits insulin secretion by opening the potassium channel through its effect on SUR1. Five of the children had undergone subtotal pancreatectomy before this study, yet continued to experience episodes of hypoglycemia with fasting for <12 h. The other three had similarly severe hypoglycemia and were controlled with frequent feedings (one via gastrostomy tube). All eight hyperinsulinemic patients had 3992 –9 g → a and DelF 1388, the two most commonly found SUR1 mutations in the Ashkenazi Jewish population (25,26); four of the children studied were homozygous for 3992 –9 g → a, and four were compound heterozygous for DelF 1388 and 3992 –9 g → a.

Control subjects included four female and two male SUR1$^{+/-}$ heterozygous carrier parents aged 36–48 years, and six female and four male normal adults aged 19–48 years. All control subjects were normoglycemic, and none had a history of diabetes. All had normal fasting blood glucose and insulin levels.

The study was reviewed and approved by the Children's Hospital of Philadelphia Institutional Review Board. Written informed consent was obtained from the subjects or their parents before participation in the study. Verbal assent was obtained from the older children.

Acute insulin responses. Subjects were admitted to the Children's Hospital of Philadelphia General Clinical Research Center. Octreotide or glucagon therapy was withdrawn for at least 24 h before study, and dextrose was infused intravenously as necessary to prevent hypoglycemia. Studies were carried out after an overnight fast, and dextrose was infused as needed to maintain the blood glucose concentration between 60 and 80 mg/dl. Two peripheral venous catheters were inserted: one for infusion and the other for blood sampling. Glucose (0.5 g/kg to a maximum of 20 g) was administered intravenously over 2 min. Twenty minutes later, tolbutamide (25 mg/kg to a maximum of 1 g) was administered intravenously over 1 min. Blood samples for glucose and insulin concentrations were obtained at –10, –5, and 0 min before the glucose bolus and at 1, 3, 5, 10, and 20 min afterwards. After the tolbutamide injection, blood samples were collected at 1, 3, 5, 10, 20, 30, 40, and 60 min. Whole blood glucose was measured by the glucose oxidase method (Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, OH). Plasma insulin concentrations were measured by microenzyme immunoparticle assay with a sensitivity of 1.0 μU/ml (Abbott IMx, Abbott Park, IL). Acute insulin

responses (AIRs) were calculated as the mean of the increment in insulin concentration at 1 and 3 min after stimulation. Glucose disposal rate was calculated from the glucose decay curve after intravenous glucose as the percent decline per minute.

Graded glucose infusion studies. Studies were performed after an overnight fast, and intravenous dextrose was administered as needed to maintain the blood glucose concentration between 60 and 80 mg/dl. Glucose was infused for a total of 4 h. Every 40 min, the rate of glucose infusion was increased from 0 to 4, 8, and 16 mg · kg^{-1} · min^{-1} and then decreased again to 8, 4, and 0 mg · kg^{-1} · min^{-1}. Blood glucose and plasma insulin concentrations were measured at baseline and every 10 min throughout the infusion. Insulin concentrations were plotted against glucose levels, resulting in two curves for each subject: the up curve corresponding to the escalating rate of dextrose infusion and the down curve to the diminishing rate of dextrose infusion that followed. Glucose sensitivity was quantified as the slope of the up curve (μU · mg^{-1} · 10^{-2}). Differences between the up and down curves were analyzed two ways. The insulin displacement was calculated as the difference between the up- and down-curve insulin concentrations at the approximate midpoint value between the peak and basal glucose concentrations (blood glucose of 150 mg/dl), expressed as a percent of the up-curve value. The second analysis used a comparison of the linear phases of the up and down curves.

Statistical analysis. All data are presented as means ± SE. An alternate Welch t test was used to compare the results between the different groups.

RESULTS

AIRs. The AIRs to glucose and tolbutamide in a normal adult and those in child number 6 with SUR1$^{-/-}$ hyperinsulinism are shown in Fig. 1A and B, respectively. The normal adult responded briskly to both stimuli, with AIRs of similar magnitude (45 μU/ml to glucose and 34 μU/ml to tolbutamide). In contrast, the SUR1$^{-/-}$ child had a smaller AIR to glucose (31 μU/ml), despite an even greater elevation in blood glucose concentration (345 vs. 290 mg/dl in the normal control), and no AIR to tolbutamide (4 μU/ml).

Table 2 compares the results of the AIR tests in the group of eight children with diffuse SUR1$^{-/-}$ hyperinsulinism, their carrier parents, and normal adults. Baseline insulin levels in the SUR1$^{-/-}$ group were comparable to those in the normal adults. AIR to tolbutamide was absent in the children with diffuse hyperinsulinism ($P < 0.005$). The 95% CI of the AIR to tolbutamide in the diffuse hyperinsulinemic patients (–2.3 to 3.7 μU/ml) did not overlap with the normal control subjects (26.4–79.7 μU/ml). Glucose stimulation provoked a positive but smaller AIR in the diffuse hyperinsulinemic patients ($P < 0.05$). The glucose disposal rates among the SUR1$^{-/-}$ children and the normal adult groups were similar. Mean insulin responses to the two AIR tests did not differ among the four children with homozygous 3992 –9 g → a mutations and the four children with compound heterozygous DelF 1388/3992 –9 g → a muta-

FIG. 1. AIRs to glucose and tolbutamide in children with diffuse SUR1$^{-/-}$ hyperinsulinism. A: Normal adult control. B: Patient 6 with diffuse SUR1$^{-/-}$ hyperinsulinism.

tions (AIR tolbutamide –0.5 ± 2 vs. 2 ± 2 µU/ml and AIR glucose 8 ± 3 vs. 20 ± 6 µU/ml, respectively). There was also no difference between the five SUR1$^{-/-}$ children who had undergone subtotal pancreatectomy and the three without surgery (AIR tolbutamide –0.1 ± 2 vs. 2 ± 1 µU/ml and AIR glucose 13 ± 4 vs. 17 ± 8 µU/ml, respectively).

As shown in Table 2, AIRs to both glucose and tolbutamide were similar in the SUR1$^{+/-}$ carriers and the normal adults. The 95% CI of the AIR to tolbutamide in the diffuse hyperinsulinemic patients did not overlap with that of the carriers (9.7–52.3 µU/ml). The glucose disposal rates of the carriers were also similar to those of the normal adults.

Insulin response to graded glucose infusion. Graded glucose infusion studies were performed in three children with SUR1$^{-/-}$ diffuse hyperinsulinism who had not undergone subtotal pancreatectomy. Surgery-naive patients were chosen for this study to eliminate subtotal pancreatectomy as a potential confounding variable that could cause impaired glucose responsiveness. Figure 2 shows the blood glucose and plasma insulin concentrations in the graded glucose infusion studies of the same SUR1$^{-/-}$ child (number 6) and normal adult control as in Fig. 1. In the normal adult (Fig. 2A), the rise and subsequent fall in blood glucose was associated

with a parallel, though slightly delayed, rise and fall in insulin concentration (peak 87 µU/ml). As shown in Fig. 2B, child number 6 with SUR1$^{-/-}$ hyperinsulinism had a similar rise and fall in blood glucose but achieved a peak insulin concentration of only 29 µU/ml despite a higher peak blood glucose concentration. Figure 3 shows the insulin concentrations plotted against blood glucose concentrations from the studies of Fig. 2. The slope of the up curve was steeper in the normal adult (37 µU · mg^{-1} · 10^{-2}) than in the child with SUR1$^{-/-}$ hyperinsulinism (4 µU · mg^{-1} · 10^{-2}), indicating diminished sensitivity to glucose for insulin secretion in the patient.

Table 3 summarizes the results of the graded glucose infusion studies in the three children with SUR1$^{-/-}$ diffuse hyperinsulinism, five SUR$^{+/-}$ carriers, and four normal adults. Because there was no difference between the carriers and normal control subjects on either AIR or on any of the graded glucose infusion parameters assessed, the two adult groups were combined for data analysis. Peak blood glucose concentration in the SUR1$^{-/-}$ children (298 ± 50 mg/dl) was equivalent to that in the adults. The peak plasma insulin concentrations in the SUR1$^{-/-}$ children overlapped the lower end of values seen in the adults, but the mean insulin concentration was significantly less in the former group ($P < 0.05$). Glucose sensitivity

TABLE 2
AIRs to glucose and tolbutamide in children with congenital hyperinsulinism

Subject group	n	Baseline plasma insulin concentration (µU/ml)	Peak blood glucose concentration (mg/dl)	AIR to glucose (µU/ml)	Glucose disposal rate (%/min)	AIR to tolbutamide (µU/ml)
Diffuse SUR1$^{-/-}$ hyperinsulinism	8	11 ± 2 (NS*)	293 ± 17 (NS)	14 ± 4 (<0.05)	2 ± 0.3 (NS)	0.7 ± 1 (<0.005)
SUR1$^{+/-}$ carriers	6	10 ± 2 (NS)	198 ± 12 (NS)	37 ± 13 (NS)	2 ± 0.2 (NS)	31 ± 8 (NS)
Normal adults	10	8 ± 1	262 ± 16	42 ± 9	2 ± 0.5	53 ± 12

Data are means ± SE (P) or means ± SE. *Significance values are presented for the difference between each group and the normal adults.

FIG. 2. Insulin response to graded glucose infusion in diffuse SUR1$^{-/-}$ hyperinsulinism. *A*: The same normal adult as in Fig. 1*A*. *B*: Patient 6 with diffuse SUR1$^{-/-}$ hyperinsulinism who had never undergone subtotal pancreatectomy. ⎯·⎯■, Glucose; ⎯⎯●, insulin.

in the SUR1$^{-/-}$ children also was less than that in the adults ($P <$ 0.01). There was no insulin displacement at 150 mg/dl glucose in the children with SUR1$^{-/-}$ hyperinsulinism. When insulin levels were plotted against blood glucose concentrations, the control subjects showed a hysteresis loop that resulted in a greater slope for the down curve compared with the up curve (124 ± 43 vs. 57 ± 13 µU · mg^{-1} · 10^{-2}; $P <$ 0.05 by a paired nonparametric test). The SUR1$^{-/-}$ children had loss of the hysteresis loop, with down slopes that were similar to the up slopes (11 ± 3 vs. 4 ± 2 µU · mg^{-1} · 10^{-2}; NS).

DISCUSSION

The results of these studies show that children with SUR1$^{-/-}$ hyperinsulinism do not respond to the insulin secretagogue, tolbutamide, and have a diminished, although positive, AIR to intravenous glucose compared with control subjects. AIR testing did not differentiate children with diffuse SUR1$^{-/-}$ hyperinsulinism homozygous for the 3992 –9 g → a mutation from those compound heterozygous for DelF 1388/3992 –9 g → a mutations. During graded glucose infusion studies, children

with diffuse SUR1$^{-/-}$ hyperinsulinism who had never undergone subtotal pancreatectomy exhibited reduced β-cell glucose sensitivity. Thus, SUR1$^{-/-}$ hyperinsulinism causes blunted but not absent glucose responsiveness. The abnormalities found on AIRs and graded glucose infusion studies of these patients were not age related because the SUR1$^{-/-}$ children were as old as 20 years and the adults as young as 19 years.

Patients with SUR1$^{-/-}$ hyperinsulinism had no AIR to tolbutamide. A previous report by Ehrlich and Martin (27) found excessive insulin release in response to intravenous tolbutamide in 15 children with idiopathic hypoglycemia. The earlier study, however, measured glucose and insulin responses from 15 to 120 min after tolbutamide and did not assess the immediate response. Furthermore, the cause(s) of hypoglycemia in these children was not known and likely represented a heterogeneous group of disorders (not necessarily diffuse SUR1$^{-/-}$ hyperinsulinism). Intravenous tolbutamide tests have also been used in the assessment of patients with insulinomas, again looking only at delayed (120–180 min) responses (28).


FIG. 3. Relationship of plasma insulin to blood glucose during graded glucose infusion. *A*: The same normal adult as in Fig. 2*A*. *B*: Patient 6 with diffuse SUR1$^{-/-}$ hyperinsulinism. The up curve for each subject corresponded to the escalating dextrose infusion, and the down curve corresponded to the subsequent diminishing dextrose infusion. ⎯⎯●, ⎯⎯■, Up curve; ⎯⎯◆, down curve.

TABLE 3
Insulin response to graded glucose infusion in unoperated children with diffuse SUR1$^{-/-}$ hyperinsulinism

	Peak blood glucose (mg/dl)	Peak plasma insulin (μU/ml)	Glucose sensitivity (μU · mg^{-1} · 10^{-2})	Insulin displacement at 150 mg/dl glucose (%)
SUR1$^{-/-}$ children				
Patient 3	350	56	0	0
Patient 5	198	18	6	0
Patient 6	345	51	4	0
Mean ± SE	298 ± 50 (NS*)	42 ± 12 ($P < 0.05$)	4 ± 2 ($P < 0.01$)	0 ± 0 ($P = 0.0001$)
Adults ($n = 9$)				
Mean ± SE	257 ± 15	120 ± 31	57 ± 13	47 ± 7
95% CI	223–292	48–191	27–86	32–63

*Significance of the difference between the mean values of the children and adults by the alternate Welch t test.

The loss of AIR to tolbutamide in children with SUR1$^{-/-}$ hyperinsulinism is not surprising given the fact that tolbutamide binds to SUR1 and these children have a lack of K$_{ATP}$ channel activity due to defective SUR1 proteins (29). Sharma et al. (30) have reported that the truncated and misfolded mutant SUR1 proteins do not transit to the plasma membrane. Similarly, these children are clinically unresponsive to treatment with diazoxide, which inhibits insulin secretion by binding to SUR1. Loss of AIR to tolbutamide can therefore serve as a diagnostic marker for children who will not benefit from diazoxide therapy, although it is remotely possible that an SUR1 mutation different from those studied here may allow the molecule to respond to one or the other ligand. Patients with mutations in Kir6.2 would be expected to have the same responses as those with SUR1 mutations, since both components of the K$_{ATP}$ channel are required for normal channel activity.

The complete loss of AIR to tolbutamide but only partial blunting of AIR to glucose provides evidence that K$_{ATP}$ channel–independent pathways are involved in glucose-mediated insulin secretion in children with SUR1$^{-/-}$ hyperinsulinism. The existence of K$_{ATP}$ channel–independent pathways has been suggested by studies of islets from rats and mice (31–33) and was recently demonstrated in human islets in vitro (34). The precise K$_{ATP}$ channel–independent pathways are still unclear (35). Proposed mechanisms include glucose-mediated elevations in intracellular calcium concentrations via mobilization of calcium sequestered in the endoplasmic reticulum (36–38). Intracellular calcium release may involve inositol-1,4,5-triphosphate (39) or the calcium release–activated nonselective cation channel (i_{CRAN}) (40,41). Furthermore, a non–calcium-dependent mechanism involving protein kinases A and C, ATP, and GTP has been suggested (42).

The reduced AIR to glucose and the diminished glucose sensitivity on graded glucose infusion studies suggest that SUR1$^{-/-}$ β-cells are less glucose responsive. Additionally, the insulin displacement at 150 mg/dl glucose is lost in children with SUR1$^{-/-}$ hyperinsulinism. Both factors may lead to postprandial hyperglycemia in children with SUR1$^{-/-}$ hyperinsulinism. These findings corroborate the clinical observation that hyperinsulinemic patients can exhibit episodes of both hypoglycemia and hyperglycemia, sometimes even in the same day. Recent studies in SUR1$^{-/-}$ knockout (and Kir6.2 knockout) mice did not have the severe hypoglycemia seen in the human disease but demonstrated a loss of first-phase and attenuated second-phase glucose-stimulated insulin secretion, consistent with the impairments in the AIR to glucose and glucose sensitivity observed in the present studies (43). Insulin secretory defects on intravenous glucose tolerance testing and graded glucose infusions have been reported in different types of maturity-onset diabetes of the young (MODY) and autosomal-dominantly inherited forms of diabetes caused by non-SUR1 single-gene mutations (44–46). In one MODY family studied, reductions in insulin secretory oscillations during prolonged glucose infusion were also detected in genetic marker–positive family members who were not yet diabetic (47). This closely resembles our children with SUR1$^{-/-}$ hyperinsulinism who, because of their single gene defect, exhibited abnormal insulin release on graded glucose infusion, but who were not diabetic. The finding of normal glucose disposal rates in the children with diffuse SUR1$^{-/-}$ hyperinsulinism suggests that they may have adapted to impaired insulin release by increasing peripheral sensitivity to insulin. The AIR to glucose did not differ between the children with diffuse SUR1$^{-/-}$ hyperinsulinism who had and those who had not undergone subtotal pancreatectomy, and the abnormal response to graded glucose infusion was found in our SUR1$^{-/-}$ hyperinsulinemic patients without surgical intervention. This finding suggests that SUR1$^{-/-}$ β-cells may contribute, independently of subtotal pancreatectomy, to the increased risk of diabetes seen in diffuse SUR1$^{-/-}$ hyperinsulinemic patients.

The children with SUR1$^{-/-}$ hyperinsulinism had no insulin displacement at 150 mg/dl glucose. It is unclear whether this signifies loss of the normal glucose potentiation of insulin release or loss of the normal lag in the suppression of the insulin secretory response to a falling glucose. It is also possible that the flat glucose sensitivity curve of the patients with diffuse SUR1$^{-/-}$ hyperinsulinism made it difficult to detect any glucose potentiation. In any case, the hysteresis loop formed by the difference in insulin levels along the up and down curves in the control subjects was not apparent in the children with SUR1$^{-/-}$ hyperinsulinism. Presumably, this observation is due to the loss of K$_{ATP}$ channel activity and provides further evidence of the glucose blindness of SUR1$^{-/-}$ β-cells. How this effect relates to the glucose potentiation of insulin secretion (48–51) is unknown. Further studies of glucose responsiveness in children with hyperinsulinism are needed to better understand how this phenomenon is altered by SUR1 mutations.

The heterozygous SUR1$^{+/-}$ carrier parents demonstrated normal insulin release on both AIRs and graded glucose infu-

sion studies. Thus, performance of AIR testing and graded glucose infusion studies on parents of children with hyperinsulinism cannot serve as a simple clinical way of identifying heterozygous carriers and thereby predicting which families potentially transmit paternal-only or autosomal recessive SUR1 mutations. The normal responses seen in the heterozygous SUR1$^{+/-}$ parents also suggest that in nonobese individuals without a history of diabetes, carrying one mutated SUR1 allele does not increase the risk of hypoglycemia or diabetes.

Because patients with the different types of hyperinsulinism follow markedly different clinical courses, including responsiveness to medical therapies such as diazoxide, identifying the type of hyperinsulinism in any given patient allows individualized tailoring of the therapeutic plan for that patient. Furthermore, the diagnosis of diffuse versus focal hyperinsulinism is currently based on histopathologic examination of subtotal pancreatectomy specimens; genetic analysis of the SUR1 mutations is still available only through research laboratories. This distinction is important because local excision in focal hyperinsulinism is far preferable to blind 95% subtotal pancreatectomy; local excision carries a lower risk of complications and is potentially curative. Complete loss of AIR to tolbutamide constitutes a potentially valuable clinical method for preoperatively identifying children with diffuse hyperinsulinism. Because children with focal hyperinsulinism also have a subpopulation of normal β-cells outside their focal lesion, they would be expected to retain an AIR to tolbutamide and have an AIR to glucose intermediate between that seen in the patients with diffuse hyperinsulinism and that seen in normal individuals. Further studies of patients with congenital hyperinsulinism at the time of diagnosis (both diffuse and focal) are needed to confirm the predictive value of the AIR to tolbutamide as a clinical marker for diffuse disease.

In summary, the loss of AIR to tolbutamide may be a useful clinical identifier of children with congenital hyperinsulinism due to diffuse SUR1$^{-/-}$ mutations. The reduced glucose responsiveness of SUR1$^{-/-}$ also has ramifications for the care of children with congenital hyperinsulinism. The primary glucose-sensing defect in diffuse SUR1$^{-/-}$ hyperinsulinism may directly contribute, independently from surgical treatment, to the increased risk of diabetes or impaired glucose tolerance in these patients. Furthermore, investigations of the insulin secretory dynamics in patients with diffuse SUR1$^{-/-}$ mutations may shed light on normal β-cell signaling. Our study provides the first in vivo evidence of the involvement of K$_{ATP}$ channel–independent pathways in glucose-mediated insulin secretion in humans.

REFERENCES

1. Glaser B, Thornton P, Otonkoski T, Junien C: Genetics of neonatal hyperinsulinism. *Arch Dis Child Fetal Neonatal Ed* 82:F79–F86, 2000
2. Stanley CA: Hyperinsulinism in infants and children. *Pediatr Clin North Am* 44:363–374, 1997
3. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matchinsky FM, Herold KC: Familial hyperinsulinism caused by an activating glucokinase mutation. *N Engl J Med* 338:226–230, 1998
4. Stanley CA, Lieu YK, Hsu BYL, Burlina AB, Greenberg CR, Hopwood NJ, Perlman K, Rich BH, Zammarchi E, Poncz M: Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. *N Engl J Med* 338:1352–1357, 1998
5. Thornton PS, Satin-Smith MS, Herold K, Glaser B, Chiu KC, Nestorowicz A, Permutt MA, Baker L, Stanley CA: Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant. *J Pediatr* 132:9–14, 1998
6. Kukuvitis A, Deal C, Arbour L, Polychronakos C: An autosomal dominant form of familial persistent hyperinsulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus. *J Clin Endocrinol Metab* 82:1192–1194, 1997
7. Thomas PM, Cote GJ, Hallman DM, Mathew PM: Homozygosity mapping to chromosome 11p of the gene for familial persistent hyperinsulinemic hypoglycemia of infancy. *Am J Hum Genet* 56:416–421, 1995
8. Thomas PM, Cote GJ, Wohllk N, Mathew PM, Gagel RF: The molecular basis for familial persistent hyperinsulinemic hypoglycemia of infancy. *Proc Assoc Am Physicians* 108:14–19, 1996
9. Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. *Science* 268:426–429, 1995
10. Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. *Human Mol Genet* 5:1809–1812, 1996
11. Nestorowicz A, Inagaki N, Gonoi T, Schoor KP, Wilson BA, Glaser B, Landau H, Stanley CA, Thornton PS, Seino S, Permutt MA: A nonsense mutation in the inward rectifier potassium channel gene, *Kir6.2*, is associated with familial hyperinsulinism. *Diabetes* 46:1743–1748, 1997
12. Inagaki N, Gonoi T, Clement JP 4th, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. *Science* 270:1166–1170, 1995
13. Dukes ID, Philipson LH: K$^+$ channels: generating excitement in pancreatic beta-cells. *Diabetes* 45:845–853, 1996
14. Shilyansky J, Cutz E, Filler RM: Endogenous hyperinsulinism: diagnosis, management, and long-term follow-up. *Semin Pediatr Surg* 6:115–120, 1997
15. Liebowitz B, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H: Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. *J Clin Endocrinol Metab* 80:386–392, 1995
16. Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS: Congenital hyperinsulinism and the surgeon: lessons learned over 35 years. *J Pediatr Surg* 34:786–793, 1999
17. Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, Junien C: Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. *J Clin Invest* 102:1286–1291, 1998
18. Ryan F, Devaney D, Joyce C, Nestorowicz A, Permutt MA, Glaser B, Barton DE, Thornton PS: Hyperinsulinism: molecular aetiology of focal disease. *Arch Dis Child* 79:445–447, 1998
19. Glaser B, Ryan F, Donath M, Landau H, Stanley CA, Baker L, Barton DE, Thornton PS: Hyperinsulinism caused by paternal-specific inheritance of a recessive mutation in the sulfonylurea-receptor gene. *Diabetes* 48:1652–1657, 1999
20. Aguilar-Bryan L, Clement JP IV, Gonzalez G, Kunjilwar K, Babenko A, Bryan J: Toward understanding the assembly and structure of KATP channels. *Physiol Rev* 78:227–245, 1998
21. Babenko AP, Aguilar-Bryan L, Bryan J: A view of sur/KIR6.X, KATP channels.

Annu Rev Physiol 60:667–687, 1998

22. Bryan J, Aguilar-Bryan L: Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels. *Biochim Biophys Acta* 1461:285–303, 1999

23. Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement JP IV, Gonzalez G, Aguilar-Bryan L, Permutt MA, Bryan J: Adenosine diphosphatase as an intracellular regulator of insulin secretion. *Science* 272:1785–1787, 1996

24. Aguilar-Bryan L, Bryan J: ATP-sensitive potassium channels, sulfonylurea receptors, and persistent hyperinsulinemic hypoglycemia of infancy. *Diabetes Rev* 4:336–343, 1996

25. Nestorowicz A, Wilson BA, Schoor KP, Inoue H, Glaser B, Landau H, Stanley CA, Thornton PS, Clement JP 4th, Bryan J, Aguilar-Bryan L, Permutt MA: Mutations in the sulfonlurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. *Human Mol Genet* 5:1813–1822, 1996

26. Glaser B, Chiu KC, Anker R, Nestorowicz A, Landau H, Ben-Bassat H, Shlomai Z, Kaiser N, Thornton PS, Stanley CA, Spielman RS, Goglin-Ewens K, Cerasi E, Baker L, Rice J, Donis-Keller H, Permutt MA: Familial hyperinsulinism maps to chromosome 11p14-15.1, 30 cM centromeric to the insulin gene. *Nat Genet* 7:185–188, 1994

27. Ehrlich RM, Martin JM: Tolbutamide tolerance test and plasma-insulin response in children with idiopathic hypoglycemia. *J Pediatr* 71:485–493, 1967

28. McMahon MM, O'Brien PC, Service FJ: Diagnostic interpretation of the intravenous tolbutamide test for insulinoma. *Mayo Clin Proc* 64:1481–1488, 1989

29. Dunne MJ, Kane C, Shepherd RM, Sanchez JA, James RF, Johnson PR, Aynsley-Green A, Lu S, Clement JP 4th, Lindley KJ, Seino S, Aguilar-Bryan L: Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. *N Engl J Med* 336:703–706, 1997

30. Sharma N, Crane A, Clement JP 4th, Gonzalez G, Babenko AP, Bryan J, Aguilar-Bryan L: The C terminus of SUR1 is required for trafficking of KATP channels. *J Biol Chem* 274:20628–20632, 1999

31. Sato Y, Aizawa T, Komatsu M, Okada N, Yamada T: Dual functional role of membrane depolarization/Ca^{2+} influx in rat pancreatic B-cell. *Diabetes* 41:438–443, 1992

32. Gembal M, Gilon P, Henquin JC: Evidence that glucose can control insulin release independently from its action on ATP-sensitive K^+ channels in mouse B cells. *J Clin Invest* 89:1288–1295, 1992

33. Best L, Yates AP, Tomlinson S: Stimulation of insulin secretion by glucose in the absence of diminished ($^{86}Rb^+$) permeability. *Biochem Pharmacol* 43:2483–2485, 1992

34. Straub SG, James RFL, Dunne MJ, Sharp GWG: Glucose activates both K_{ATP} channel-dependent and K_{ATP} channel-independent signaling pathways in human islets. *Diabetes* 47:758–763, 1998

35. Shepherd RM, Cosgrove KE, O'Brien RE, Barnes PD, Ammala C, Dunne MJ: Hyperinsulinism of infancy: towards an understanding of unregulated insulin release. *Arch Dis Child Fetal Neonatal Ed* 82:F87–F97, 2000

36. Roe MW, Lancaster ME, Mertz RJ, Worley JF III, Dukes ID: Thapsigargin inhibits the glucose-induced decrease of intracellular Ca^{2+} in mouse islets of Langerhans. *Am J Physiol* 266:E852–E862, 1994

37. Hamakawa N, Tada T: Interplay of glucose-stimulated Ca^{2+} sequestration and acetylcholine-induced Ca^{2+} release at the endoplasmic reticulum in rat pancreatic β-cells. *Cell Calcium* 17:21–31, 1995

38. Dukes ID: Calcium influx and efflux pathways in insulin-secreting cells (Abstract). *Biophys J* 64:A127, 1993

39. Gromada J, Frokjaer-Jensen J, Disseng S: Glucose stimulates voltage- and calcium-dependent inositol triphosphate production and intracellular calcium mobilization in insulin-secreting BTC3 cells. *Biochem J* 314:339–345, 1996

40. Worley JF III, McIntyre MS, Spencer B, Dukes ID: Depletion of intracellular Ca^{2+} stores activates a maitotoxin-sensitive nonselective cationic current in β-cells. *J Biol Chem* 269:32055–32058, 1994

41. Roe MW, Worley JF III, Qian F, Mittal AA, Mertz RJ, Philipson LH, Dukes ID: Characterization of a Ca^{2+} release-activated nonselective cation current regulating membrane potential and $[Ca^{2+}]_i$ oscillations in transgenic-derived β-cells. *J Biol Chem* 273:10402–10410, 1998

42. Yajima H, Komatsu M, Schermerhorn T, Aizawa T, Kaneko T, Nagai M, Sharp GW, Hashizume K: cAMP enhances insulin secretion by an action on the ATP-sensitive K+ channel-independent pathway of glucose signaling in rat pancreatic islets. *Diabetes* 48:1006–1012, 1999

43. Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J: Sur1 knockout mice: a model for K(ATP) channel-independent regulation of insulin secretion. *J Biol Chem* 275:9270–9277, 2000

44. Byrne MM, Sturis J, Clement K, Vionnet N, Pueyo ME, Stoffel M, Takeda J, Passa P, Cohen D, Bell GI, Velho G, Froguel P, Polonsky KS: Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. *J Clin Invest* 93:1120–1130, 1994

45. Byrne MM, Sturis J, Menzel S, Yamagata K, Fajans SS, Dronsfield MJ, Bain SC, Hattersley AT, Velho G, Froguel P, Bell GI, Polonsky KS: Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. *Diabetes* 45:1503–1510, 1996

46. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS: Maturity-onset diabetes of the young. *Life Sci* 55:413–422, 1994

47. Herman WH, Fajans SS, Ortiz FJ, Smith MJ, Sturis J, Bell GI, Polonsky KS, Halter JB: Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. *Diabetes* 43:40–46, 1994

48. Wajngot A, Alvarsson M, Glaser A, Efendic S, Luthman H, Grill V: Glucose potentiation of arginine-induced insulin secretion is impaired in subjects with a glucokinase Glu256Lys mutation. *Diabetes* 43:1402–1406, 1994

49. McCulloch DK, Raghu PK, Johnston C, Klaff LJ, Kahn SE, Beard JC, Ward WK, Benson EA, Koerker DJ, Bergman RN, Palmer JP: Defects in beta-cell function and insulin sensitivity in normoglycemic streptozocin-treated baboons: a model of preclinical insulin-dependent diabetes. *J Clin Endocrinol Metab* 67:785–792, 1988

50. McRae JR, Metz SA, Robertson RP: A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics. *Metabolism* 30:1065–1075, 1981

51. Efendic S, Lins PE, Cerasi E: Potentiation and inhibition of insulin release in man following priming with glucose and with arginine: effect of somatostatin. *Acta Endocrinol* 90:259–271, 1979